

Issue of Equity

Sydney, Australia – 6 October 2023: Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) announces that today it has issued 1,875,000 fully paid ordinary shares (“Shares”) at an offer price of \$0.08 per Share and 937,500 unquoted options with an exercise price of \$0.10 expiring on 30 June 2024 (“Options”) to a nominee of non-executive Chair, David Baker.

All Shares and Options were issued following shareholder approval under ASX LR10.11 at an extraordinary general meeting (“EGM”) of the Company held on 3 October 2023. For further information please refer to Resolution 3 in the Notice of EGM announced on the ASX on 31 August 2023 and the ASX Announcement released on 3 August 2023.

An Appendix 2A in relation to the quotation of the Shares and Appendix 3G in relation to the issue of the Options will be lodged with the ASX later today. An Appendix 3Y in respect of the change of directors’ interests is attached to this announcement.

Cleansing Statement

This notice is given by the Company under section 708A(5)(e) of the Act.

On the date of this notice, the Company issued a total of 1,875,000 Shares in the capital of Bod Science Limited without disclosure to an investor under Part 6D.2 of the Act. As per section 708A(6) of the Act, the Company advises that:

- (a) as at the date of this notice, the Company has complied with:
 - i. the provisions of Chapter 2M of the Act as they apply to the Company; and
 - ii. section 674 and section 674A of the Act.
- (b) as at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Act.

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	BOD SCIENCE LIMITED
ABN	89 601 225 441

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	David Baker
Date of last notice	10 March 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	David Baker has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities of Baker Cook Advisory Pty Ltd ACN 002 930 387 <Baker Cook Superannuation Fund>.
Date of change	6 October 2023
No. of securities held prior to change Baker Cook Advisory Pty Ltd ACN 002 930 387 <Baker Cook Superannuation Fund>*	4,500,000 Fully paid ordinary shares (Shares) 750,000 unlisted options exercisable at \$0.16 per option and expiring on 30 November 2025 (\$0.16 Options)
Class	1. Shares 2. Unlisted options exercisable at \$0.10 per option and expiring on 30 June 2024 (\$0.10 Options)
Number acquired	1. 1,875,000 Shares 2. 937,500 \$0.10 Options
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	1. \$0.08 per Share 2. Nil per \$0.10 Option. Free attaching option pursuant to the Placement

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change Baker Cook Advisory Pty Ltd ACN 002 930 387 <Baker Cook Superannuation Fund>* * David Baker has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, the securities	6,375,000 Shares 750,000 \$0.16 Options 937,500 \$0.10 Options
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Shares and free attaching \$0.10 Options on the terms of the Placement announced on 3 August 2023, following shareholder approval on 3 October 2023.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
---	----

⁺ See chapter 19 for defined terms.

If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.